DGK-κ Activators
DGK-κ activators encompass a collection of chemical entities that indirectly facilitate the kinase's functional activity by modulating intracellular signaling cascades and lipid metabolism. Phorbol 12-myristate 13-acetate (PMA), 1,2-Dioctanoyl-sn-glycerol (DiC8), Bryostatin 1, Oleoylethanolamide (OEA), and Arachidonic acid orchestrate their effects through the activation of protein kinase C (PKC). As PKC consumes diacylglycerol (DAG) to propagate signaling, these activators indirectly necessitate the action of DGK-κ to replenish DAG pools, thus enhancing its activity. Ionomycin, by increasing intracellular calcium, can activate calcium-dependent isoforms of DGK, including DGK-κ, thus amplifying its activity in a calcium-rich environment. Similarly, ceramide and Sphingosine-1-phosphate (S1P) modulate protein phosphatases and PKC activity, respectively, which can indirectly lead to an upregulation of DGK-κ activity due to its central role in DAG turnover. Compounds such as Bisindolylmaleimide I (BIM), by inhibiting PKC, prevent the excessive depletion of DAG, thereby maintaining a substrate level conducive to DGK-κ activation.
Moreover, Retinoic acid and Calcitriol (Vitamin D3) exert influence over PKC isoforms, thereby indirectly modulating DGK-κ activity through their effects on intracellular signaling pathways that intersect with lipid metabolism. The nuanced balance of DAG and phosphatidic acid (PA) is crucial for cellular signaling, and DGK-κ is pivotal in this process. Dibutyryl-cAMP (db-cAMP), as a cAMP analog, can activate PKA, which may phosphorylate and regulate proteins that interact with DGK-κ, thereby potentially enhancing the kinase's activity through these regulatory mechanisms. Collectively, these chemical activators, through their targeted and diverse mechanisms of action, serve to potentiate DGK-κ activity, crucial for maintaining cellular homeostasis through the dynamic modulation of DAG and PA levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $47.00 $254.00 | 2 | |
DiC8 is a synthetic analog of DAG that can activate PKC. By mimicking DAG and activating PKC, DiC8 can potentially lead to an enhancement of DGK-κ activity as the enzyme works to counterbalance the levels of DAG in the cell. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate certain isoforms of DGK, including DGK-κ, as it is a calcium-dependent kinase. This enhanced calcium presence can therefore indirectly upregulate DGK-κ activity. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a PKC agonist that, like PMA, leads to the activation of PKC and subsequent depletion of DAG levels. This can induce a compensatory increase in DGK-κ activity to replenish DAG through its kinase activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a metabolite of vitamin A, has been shown to influence the activity of various PKC isoforms. By altering PKC activity, retinoic acid can indirectly affect DGK-κ activity due to its role in DAG metabolism. | ||||||
Oleylethanolamide | 111-58-0 | sc-201400 sc-201400A | 10 mg 50 mg | $90.00 $194.00 | 1 | |
OEA is a naturally occurring ethanolamide lipid that can act as a PKC activator. By promoting PKC activity and thus influencing DAG levels, OEA can indirectly lead to the enhancement of DGK-κ activity. | ||||||
C2 Ceramide | 3102-57-6 | sc-201375 sc-201375A | 5 mg 25 mg | $124.00 $460.00 | 12 | |
Ceramide can activate protein phosphatases, which in turn can dephosphorylate and activate certain PKC isoforms. This can ultimately affect DGK-κ activity by influencing the turnover of DAG. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
Arachidonic acid can be released from membrane phospholipids upon phospholipase A2 activation and can modulate various PKC isoforms. This modulation can affect DGK-κ indirectly due to its role in managing intracellular DAG levels. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P, a bioactive lipid, can influence various signaling pathways, including those involving PKC. By modulating PKC activity, S1P can potentially affect DGK-κ activity as the enzyme is involved in the regulation of DAG, which is a substrate for PKC. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $220.00 $645.00 $1000.00 $1500.00 $440.00 | 32 | |
Calcitriol, the active form of vitamin D3, has been implicated in regulating PKC activity in certain cellular contexts. By modulating PKC, calcitriol can have an indirect effect on DGK-κ activity by impacting DAG metabolism. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cAMP analog that activates PKA, which in turn can phosphorylate and regulate proteins that might interact with or regulate DGK-κ, thereby potentially enhancing the activity of DGK-κ through these interactions. | ||||||